Leri 1994.

Methods	Generation of allocation sequence: unclear (no description). Allocation concealment: unclear (no description). Double blinding: unclear (no description). Sample size calculation: no. Follow up: adequate (no drop out). Intention‐to‐treat analysis: not performed.
Participants	Country: Italy. Type of hepatitis: chronic hepatitis C. INCLUSION CRITERIA ‐ anti‐HCV positive; ‐ liver biopsy scoring were assessed before the treatment and showed periportal necrosis, lobular and portal inflammation, according to chronic hepatitis. PARTICIPANTS ‐ UDCA group (n = 12): Mean age (years) 59.17. Ratio of sex (M/F) 5/7. Proportion of patients with cholestasis: no information. Proportion of patients with cirrhosis: no information. ‐ Placebo group (n = 10): Mean age (years) 56.40; Ratio of sex (M/F) 5/5. Proportion of patients with cholestasis: no information. Proportion of patients with cirrhosis: no information.
Interventions	UDCA group: UDCA ‐ Dose: 600 mg/day; ‐ Route: Orally; ‐ Timing: no information; ‐ Duration: six months. Placebo group: ‐ Placebo.
Outcomes	‐ Serum AST, ALT, and GGT activities at the end of treatment.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear